Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma
Victor Joo(University Hospital of Lausanne), Michel Obéid(University Hospital of Lausanne)
Cited by 11
Related Papers
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
|Nature Reviews Clinical Oncology|2019|2.2k
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy
|Annals of Oncology|2020|230
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy
|Journal for ImmunoTherapy of Cancer|2020|164
Immune checkpoint inhibitor-associated myocarditis: a novel risk score
|European Heart Journal|2025|34